Please try another search
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.
Name | Age | Since | Title |
---|---|---|---|
Debra A. Goff | - | 2016 | Member of Clinical Advisory Board |
James W. Snyder | - | - | Member of Clinical Advisory Board |
Stefan Riedel | - | 2016 | Member of Clinical Advisory Board |
Patricia Simner | - | - | Member of Clinical Advisory Board |
Avraham Shlomo Ben-Tzvi | 53 | 2024 | Director |
David Natan | 71 | 2024 | Director |
David Elliot Lazar | 33 | 2024 | CEO & Chairman |
Matthew C. McMurdo | 51 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review